As a critical transcription factor involved in epithelial-mesenchymal transition, TWIST1 overexpression can enhance the susceptibility to chemotherapy drugs by promoting cell cycle entry and, thus, improve AML patients’ outcomes (Chen et al., 2015; Wang et al., 2015). Here, TWIST1 is linked to acute myeloid leukemia.